视觉估计与图像融合靶向前列腺穿刺活检对临床显著性前列腺癌检出率的比较
这项多中心研究比较了视觉估计(认知配准)与图像融合(软件配准)靶向经会阴前列腺穿刺活检对临床显著性前列腺癌的检出率。共纳入1071例仅靶向穿刺患者和770例靶向联合系统穿刺患者,经倾向性评分匹配后总体检出率无显著差异,但高年资泌尿外科医生使用图像融合的检出率显著更高。
要点
- 总体而言,视觉估计与图像融合靶向穿刺对临床显著性前列腺癌的检出率无显著差异。
- 高年资泌尿外科医生使用图像融合的检出率显著高于视觉估计。
- 选择穿刺方式时需考虑操作者经验。
核心结论
- 视觉估计与图像融合靶向经会阴前列腺穿刺活检对临床显著性前列腺癌的总体检出率无显著差异。
- 图像融合可能在高年资泌尿外科医生手中更具优势。
研究设计与样本
- 多中心研究,纳入2017年4月至2020年3月期间接受视觉估计或图像融合靶向经会阴前列腺穿刺活检的多参数磁共振成像病灶患者。
- 仅靶向穿刺组1071例(视觉估计372例,图像融合699例),靶向联合系统穿刺组770例(视觉估计271例,图像融合499例)。
- 采用倾向性评分匹配人口学、临床特征、多参数磁共振成像变量和穿刺因素。
主要发现
- 匹配比较显示视觉估计与图像融合的临床显著性前列腺癌检出率总体无差异(主要阈值Gleason≥3+4:仅靶向穿刺54% vs 57.4%,p=0.302;靶向联合系统穿刺51.2% vs 58.2%,p=0.123)。
- 高年资泌尿外科医生使用图像融合的检出率显著更高(主要阈值:仅靶向穿刺45.4% vs 63.7%,p=0.001;靶向联合系统穿刺39.4% vs 64.5%,p<0.001)。
临床怎么用
- 对于高年资泌尿外科医生,图像融合靶向穿刺可能提高临床显著性前列腺癌的检出率。
- 视觉估计与图像融合均可用于靶向穿刺,但需结合操作者经验进行选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We compared clinically significant prostate cancer detection by visual estimation and image fusion targeted transperineal prostate biopsy. MATERIALS AND METHODS: This multicenter study included patients with multiparametric magnetic resonance imaging lesions undergoing visual estimation or image fusion targeted transperineal biopsy (April 2017-March 2020). Propensity score matching was performed using demographics (age and ethnicity), clinical features (prostate specific antigen, prostate volume, prostate specific antigen density and digital rectal examination), multiparametric magnetic resonance imaging variables (number of lesions, PI-RADS® score, index lesion diameter, whether the lesion was diffuse and radiological T stage) and biopsy factors (number of cores, operator experience and anesthetic type). Matched groups were compared overall and by operator grade, PI-RADS score, lesion multiplicity, prostate volume and anesthetic type using targeted-only and targeted plus systematic histology. Multiple clinically significant prostate cancer thresholds were evaluated (primary: Gleason ≥3+4). RESULTS: A total of 1,071 patients with a median age of 67.3 years (IQR 61.3-72.4), median prostate specific antigen of 7.5 ng/ml (IQR 5.3-11.2) and 1,430 total lesions underwent targeted-only biopsies (visual estimation: 372 patients, 494 lesions; image fusion: 699 patients, 936 lesions). A total of 770 patients with a median age of 67.4 years (IQR 61-72.1), median prostate specific antigen of 7.1 ng/ml (IQR 5.2-10.6) and 919 total lesions underwent targeted plus systematic biopsies (visual estimation: 271 patients, 322 lesions; image fusion: 499 patients, 597 lesions). Matched comparisons demonstrated no overall difference in clinically significant prostate cancer detection between visual estimation and image fusion (primary: targeted-only 54% vs 57.4%, p=0.302; targeted plus systematic 51.2% vs 58.2%, p=0.123). Senior urologists had significantly higher detection rates using image fusion (primary: targeted-only 45.4% vs 63.7%, p=0.001; targeted plus systematic 39.4% vs 64.5%, p <0.001). CONCLUSIONS: We found no overall difference in clinically significant prostate cancer detection, although image fusion may be superior in experienced hands.
引用
- Khoo CC, Eldred-Evans D, Peters M, et al. A Comparison of Prostate Cancer Detection between Visual Estimation (Cognitive Registration) and Image Fusion (Software Registration) Targeted Transperineal Prostate Biopsy. J Urol. 2020. PMID: 33207137. doi:10.1097/JU.0000000000001476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。